Multiple Sclerosis is an autoimmune disorder that involves recurring inflammatory attacks on the central nervous system. This is caused by a dysfunctional immune system and leads to neurological disability. Multiple Sclerosis is a result of complex genetic and environmental factors, however, the exact cause has never been determined.
This disease is inflammatory demyelination of the CNS and can be characterized by lymphocyte and macrophage infiltrates as well as glial cell activation. Diffuse inflammatory lesions, also known as plaques, are a key indicator of MS and are found ob optic nerves, in the spinal cords, brainstem, periventricular white matter, and grey matter.
Patients of MS can be grouped into four main categories: relapse-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive relapsing MS (PRMS). The market for multiple sclerosis treatment is competitive and there are 14 available treatment options, most of which are immunomodulatory agents.
Multiple Sclerosis: Global Drug Forecast and Market Analysis to 2028 by GlobalData explores how most treatments for the disorder currently focus on inflammation rather than neuroprotective properties, creating unmet needs in the market. From 2018-2028, the MS market will grow at a CAGR of 5.2% to a value of $32.9B. This rise will be driven by 11 new pipeline products.
Key highlights of the report include:
- Overview of MS epidemiology, etiology, diagnosis, and disease management
- Strategic competitor assessment, market characterization, and unmet needs
- Pipeline analysis of MS drugs and emerging trends in the development of drugs
- Analysis of current and future market competition in the global MS market
Use this report to gain an insight into the pipeline drugs currently in development for MS treatment. Learn about the impact of MS and ensure that you are able to channelize resources to maximize success.
GlobalData is this website’s parent business intelligence company.